Publications Archives - Page 3 of 25

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions

by admin | Jul 10, 2019

Dedic N, Jones P.G, Hopkins S.C, Lew R, Shao L, Campbell J. E, Spear K. L, Large T. H, Campbell U. C, Hanania T, Leahy E, Koblan K Journal of Pharmacology and Experimental Therapeutics. August 1, 2019 jpet.119.260281. For the past 50 years, the clinical efficacy of...

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease

by admin | Jul 9, 2019

Zeitler B, Froelich S, Marlen K, Shivak D.A, Yu Q, Li D, Pearl J.R, Miller J.C, Zhang L, Paschon D.E, Hinkley S.J, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone J.M, Nguyen B.H.O, Qiao G, Ataei Y, Mendel M.C, Amora R, Surosky R, Laganiere J, Vu B.J , Narayanan A,...

Validated Phenotypic Approach to Neuropsychiatric Drug Discovery

by admin | Mar 1, 2019

Leahy E Drug Development & Delivery March 2019 Vol 19 No 2: 46-49. At the recent American College of Neuropsychopharmacology (ACNP) meeting, Sunovion Pharmaceuticals and PsychoGenics Inc. announced positive Phase 2 results for SEP-363856, a novel, first-in-class...

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain

by admin | Feb 1, 2019

Kwan M Y, Choo A, Hanania T, Ghavami A, Beltran J, Shea J, Barboza A, Hu A, Fowler M, Rao N V, Sucholeiki I Int J Mol Sci. 2019 Feb; 20(4): 811. Published online 2019 Feb 14. doi: 10.3390/ijms20040811. There is an unmet medical need for the development of...

Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E

by admin | Oct 1, 2018

Lancaster, Li J, Hanania T, Liem R, Scheideler M. A, Scherer S. Experimental Neurology 2018 Oct;308:13-25. doi: 10.1016/j.expneurol.2018.06.010. Epub 2018 Jun 22. We have analyzed a mouse model of Charcot-Marie-Tooth disease 2E (CMT2E) harboring a heterozygous...

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease

Validated Phenotypic Approach to Neuropsychiatric Drug Discovery

Biomarker Analysis of Orally Dosed, Dual Active, Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitor, AQU-118, in the Spinal Nerve Ligation (SNL) Rat Model of Neuropathic Pain

Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E

Recent Comments

CONTACT